BCL-x

Cancer letters (2017-09-28)

Sara Fatima Faqar-Uz-Zaman, Ulrike Heinicke, Michael Torsten Meister, Meike Vogler, Simone Fulda

ABSTRACT

BH3 mimetics are a promising new class of anticancer agents that inhibit antiapoptotic BCL-2 proteins. Here, we report that BH3 mimetics selectively targeting BCL-x

MATERIALS

Product Number

Brand

Product Description

T5428

Sigma-Aldrich

テトラメチルローダミンメチルエステルパークロレート, ≥95%